When it has spread: kidney, upper tract, testis and penile

Four cancers, four different labels underneath the word advanced. Adjuvant platinum after nephroureterectomy and why POUT’s survival claim is weaker than it is usually quoted; CARMENA and the narrow place cytoreductive nephrectomy still holds; why you say which kidney risk model you used; the retroperitoneal node dissection, where the template depends on the side and the chemotherapy depends on the risk group; what is actually injured when ejaculation fails afterwards; when rising markers mean salvage chemotherapy rather than surgery; why clinical N3 penile cancer never starts with the knife; and one drug that is standard of care in one of these cancers and a strong recommendation against in another.